Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px
Document › Details

Protagen Protein Services GmbH. (4/10/19). "Press Release: Protagen Protein Services and BioAnalytix Merge to Create Global Analytic Service Partner for Biopharmaceuticals". Heilbronn & Boston, MA.

Organisations Organisation Protagen Protein Services GmbH (PPS)
  Today ProtaGene GmbH
  Group ProtaGene (Group)
  Organisation 2 BioAnalytix Inc.
  Today ProtaGene US Inc.
  Group ProtaGene (Group)
Products Product mass spectrometry-based analysis of biopharmaceutical
  Product 2 proteomic services
Index term Index term BioAnalytix–Zukunftsfonds Heilbronn: investment, 201904 merger acquisition of BioAnalytix Inc by Protagen Protein Services GmbH
Persons Person Blüggel, Martin (Protagen Protein Services 201904 CEO + Founder)
  Person 2 Poss, Kirtland (Kirt) (BioAnalytix 201201– CEO before T2 Biosystems + VisEn Medical 2000– CEO + Co-founder)
     


Protagen Protein Services GmbH (PPS), a full-service contract research organization (CRO) in protein analytics and BioAnalytix Inc., a Cambridge (MA)-based specialized provider of advanced analytics in biologic development announced today a merger that will transform the combined company into a leading global analytic CRO. Today’s announcement creates a best-in-class partner for the biopharmaceutical industry worldwide to benefit from the most advanced, integrated and complete analytic services capabilities and platforms in biopharmaceutical development, from clone selection through drug approval to commercialization.

In working together with its pharmaceutical partners, the PPS and BioAnalytix teams generate best-in-class analytic data packages and provide scientific, technical and regulatory support to advance, de-risk and accelerate all stages of biopharmaceutical development including biosimilar development at highest quality from clone through clinic.

Martin Blüggel, Founder and CEO of PPS, stated “Both companies have shared a similar vision, entrepreneurial agility and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development. We are fascinated to serve our pharma partners more directly in the FDA and EMEA territories, and continue our expansion in capacities and capabilities now including BioAnalytix’s innovative areas such as HDX-MS and in-vivo CQA Mapping.”

Kirtland Poss, Founder and CEO of BioAnalytix added, “We’re thrilled about the combination of the companies and their analytic offerings. The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we strengthen our focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners.”

By combining analytic platforms, programs and highly experienced teams based both in US and in Europe, PPS and BioAnalytix will work directly and more broadly with leading biopharmaceutical companies in designing, generating and delivering integrated analytical data packages, and strategic support along the full development continuum, from developabilityand lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and CMC filings through commercialization and full GMP testing of commercial products.


About Protagen Protein Services

Protagen Protein Services GmbH (PPS) is a leading CRO and a recognized expert for GMP compliant protein analytical services. More than 20 years of market experience and the comprehensive spectrum of analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry. For developing innovative biologics PPS supports customer by all-in-one-hand service including full analytical support, complete documentation and outstanding project management.PPS supports biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating biosimilarity.


About BioAnalytix

BioAnalytix, Inc. is a specialty analytic services company working with leading biotherapeutic companies in the development and application of advanced analytics and data analysis of complex biologics. Based in Cambridge, MA and becoming part of Protagen Protein Services GMBH, Germany in 2019, BioAnalytix’s programs are oriented around hybrid LC-MS, physical chemistry and data analysis platforms for precisely characterizing complex biotherapeutics from candidate selection through commercialization

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for ProtaGene (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x300px




» top